CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 6, 2020--
Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that the Company's Cadence-1 study will be highlighted in a poster presentation at the 3 rd Pan American Parkinson’s Disease and Movement Disorders Congress from February 14-16, 2020 at the InterContinental Miami in Miami, Florida.
The poster, titled “ Phase 2a Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of CAD-1883 in Essential Tremor (Cadence-1),” will be presented on Saturday, February 15, 2020, from 1:00 PM to 2:30 PM in the Biscayne Ballroom at the InterContinental Miami.
About Cadent Therapeutics
Cadent Therapeutics is creating therapies for the treatment of movement, mood, and cognitive disorders. The company combines target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders. Cadent Therapeutics is rapidly advancing its pipeline of positive allosteric modulators to treat spinocerebellar ataxia, essential tremor, and schizophrenia. The company has an exclusive license and collaboration agreement with Novartis to develop a negative allosteric modulator, now in Phase 2 for the treatment of treatment resistant depression. Investors include Atlas Venture, Cowen Healthcare Investments, Qiming Venture Partners, Access Industries, Clal Biotechnology Industries, Novartis Corporate and Slater Technology Fund. For more information, please visit cadenttx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20200206005107/en/
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY MENTAL HEALTH HEALTH PHARMACEUTICAL CLINICAL TRIALS
SOURCE: Cadent Therapeutics
Copyright Business Wire 2020.
PUB: 02/06/2020 04:05 PM/DISC: 02/06/2020 04:05 PM